Ensign Peak Advisors
BNR

Ensign Peak Advisors’s Burning Rock Biotech BNR Stock Holding History

Ensign Peak Advisors’s Portfolio BNR Stock Details BNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-305
Closed -$29K – 2212
2021
Q4 		$29K Hold
305
– – ﹤0.01% 2170
2021
Q3 		$55K Hold
305
– – ﹤0.01% 1828
2021
Q2 		$90K Buy
+305
New +$90.2K ﹤0.01% 1786

Other funds holding BNR

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ensign Peak Advisors's BNR Position: Q1 2022 in Review

Ensign Peak Advisors sold out of Burning Rock Biotech (BNR) in Q1 2022, closing a stake of 305 shares — an estimated $29K sold.

Ensign Peak Advisors first reported a position in BNR in Q2 2021 and held it in 3 quarters. The position peaked at $90K in Q2 2021. 46 funds tracked by Wall St. Rank hold BNR as of Q1 2022.

  • Ensign Peak Advisors reported no remaining Burning Rock Biotech position as of Q1 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 305 Burning Rock Biotech shares in Q1 2022, an estimated $29K.
  • Ensign Peak Advisors first reported a position in Burning Rock Biotech in Q2 2021 and held it in 3 quarters.
  • Ensign Peak Advisors's Burning Rock Biotech position peaked at $90K in Q2 2021.
  • 46 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q1 2022.

Based on Ensign Peak Advisors's 13F filing for Q1 2022, filed 16 May 2022.